Klingman & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Klingman & Associates's VRTX Position: Q2 2026 in Review
Klingman & Associates increased its Vertex Pharmaceuticals (VRTX) stake by 3.4% in Q2 2026, buying an estimated $7.98K and bringing the position to 547 shares worth $272K. The position accounts for 0.01% of the portfolio, ranked #285.
Klingman & Associates first reported a position in VRTX in Q2 2025 and has held it in 4 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Klingman & Associates held 547 shares of Vertex Pharmaceuticals worth $272K as of Q2 2026.
- Klingman & Associates bought 18 Vertex Pharmaceuticals shares in Q2 2026, an estimated $7.98K.
- Vertex Pharmaceuticals made up 0.01% of Klingman & Associates's portfolio in Q2 2026, its #285 holding.
- Klingman & Associates first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Klingman & Associates's 13F filing for Q2 2026, filed 29 Jul 2026.